top of page
Home
Research
Basilea
About
Blog
Contact
Sign up
Â
Use tab to navigate through the menu items.
All Posts
Search
Andrew Keith
8 hours ago
Basilea - Going for growth
Brian White
Feb 18
Another year of strong execution
Andrew Keith
Feb 5
Basilea - Cresemba's new high
Brian White
Jan 28
Basilea - A breadth of demand
Brian White
Jan 8
Basilea - Infectious success
Brian White
Dec 23, 2024
Basilea - Non-dilutive antibiotic funding
Brian White
Dec 16, 2024
Basilea - Ceftobiprole partner secured
Andrew Keith
Nov 18, 2024
PureTech Health - Patient Capital?
Andrew Keith
Oct 23, 2024
Basilea - A Perfect Match
Brian White
Sep 24, 2024
Basilea - Fosmanogepix Phase 3 begins
Andrew Keith
Sep 19, 2024
Basilea - Significant BARDA funding
Brian White
Sep 6, 2024
Further Cresemba sales success
Andrew Keith
Aug 29, 2024
Basilea research report
Brian White
Aug 27, 2024
Cresemba's market exclusivity extension
Brian White
Aug 13, 2024
Gaining momentum in H1 2024
Brian White
May 16, 2024
Basilea - Cresemba APAC milestone
Brian White
May 3, 2024
Basilea - Fleshing out Zevtera
Brian White
Apr 4, 2024
Zevtera FDA approval
Andrew Keith
Feb 28, 2024
Basilea research report
Brian White
Feb 13, 2024
Basilea full-year results - Strong execution
bottom of page
